Carmat (ALCAR) - Cash Flow Conversion Efficiency

Latest as of December 2024: 0.344x

Based on the latest financial reports, Carmat (ALCAR) has a cash flow conversion efficiency ratio of 0.344x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.58 Million ≈ $-20.56 Million USD) by net assets (€-51.13 Million ≈ $-59.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALCAR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Carmat - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Carmat's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Carmat Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Carmat ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
FIRST LITHIUM MINERALS
F:X28
-0.160x
Lifecare AS
OL:LIFE
3.325x
Daekyo Co Ltd
KO:019685
0.035x
Loyal Solutions AS
ST:LOYAL
0.017x
Henderson Far East Income Ltd
LSE:HFEL
0.025x
Henderson Smaller Cos Inv Tst
LSE:HSL
0.009x
Charan Insurance Public Company Limited
BK:CHARAN
0.003x
GENINCODE PLC LS -01
F:9PL
N/A

Annual Cash Flow Conversion Efficiency for Carmat (2010–2024)

The table below shows the annual cash flow conversion efficiency of Carmat from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Carmat (ALCAR) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €-51.13 Million
≈ $-59.78 Million
€-43.31 Million
≈ $-50.64 Million
0.847x -30.68%
2023-12-31 €-43.76 Million
≈ $-51.16 Million
€-53.48 Million
≈ $-62.52 Million
1.222x +104.05%
2022-12-31 €1.80 Million
≈ $2.11 Million
€-54.38 Million
≈ $-63.57 Million
-30.175x -788.21%
2021-12-31 €-13.72 Million
≈ $-16.04 Million
€-60.17 Million
≈ $-70.34 Million
4.385x +179.66%
2020-12-31 €7.82 Million
≈ $9.14 Million
€-43.03 Million
≈ $-50.31 Million
-5.504x -232.89%
2019-12-31 €24.34 Million
≈ $28.46 Million
€-40.24 Million
≈ $-47.05 Million
-1.653x +11.04%
2018-12-31 €20.54 Million
≈ $24.01 Million
€-38.17 Million
≈ $-44.63 Million
-1.859x -337.96%
2017-12-31 €57.21 Million
≈ $66.88 Million
€-24.28 Million
≈ $-28.38 Million
-0.424x +42.37%
2016-12-31 €28.89 Million
≈ $33.77 Million
€-21.27 Million
≈ $-24.87 Million
-0.736x +93.99%
2015-12-31 €1.40 Million
≈ $1.64 Million
€-17.19 Million
≈ $-20.09 Million
-12.248x -407.32%
2014-12-31 €7.76 Million
≈ $9.08 Million
€-18.75 Million
≈ $-21.92 Million
-2.414x -81.08%
2013-12-31 €7.23 Million
≈ $8.45 Million
€-9.64 Million
≈ $-11.27 Million
-1.333x +26.17%
2012-12-31 €9.94 Million
≈ $11.62 Million
€-17.95 Million
≈ $-20.99 Million
-1.806x -400.34%
2011-12-31 €26.89 Million
≈ $31.44 Million
€-9.71 Million
≈ $-11.35 Million
-0.361x +19.55%
2010-12-31 €15.49 Million
≈ $18.11 Million
€-6.95 Million
≈ $-8.13 Million
-0.449x --

About Carmat

PA:ALCAR France Medical Devices
Market Cap
$7.44 Million
€6.36 Million EUR
Market Cap Rank
#28059 Global
#505 in France
Share Price
€0.10
Change (1 day)
+0.00%
52-Week Range
€0.10 - €0.62
All Time High
€53.45
About

Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.